Highest-materiality recent filing
Autonomix Medical raises $4.9M via warrant exercise, issues Series E warrants
Gross proceeds ~$4.9M from exercise of 857,462 shares at $5.75 per share; close expected Aug 26, 2026.
Autonomix Medical raises $2.6M via warrant exercise inducement; issues new warrants
Gross proceeds of ~$2.6M from immediate cash exercise of 428,731 existing Series C warrants at reduced price of $6.00/share.
Autonomix Medical receives Nasdaq bid price deficiency notice; 180-day cure period
Received Nasdaq letter on Jan 14, 2026: bid price below $1.00 for 30 consecutive business days.
Autonomix reports pancreatic cancer pain relief across all stages in PoC study at ASCO GI 2026
Rapid pain reduction within 24 hours of transvascular RF denervation procedure.
Autonomix Medical raises $5.0M via private placement of pre-funded and Series C warrants
Gross proceeds of ~$5.0M from sale of pre-funded warrants (4,501,666 shares at $0.001) and Series C warrants (9,003,332 shares at $0.8607).
Autonomix Medical stockholders approve reverse split, expanded equity plan at annual meeting
All five director nominees elected; Forvis Mazars ratified as auditor for FY ending Mar 2026.
Autonomix Medical enters $15M equity purchase agreement with Lincoln Park Capital
Lincoln Park committed to purchase up to $15M in common stock over 24 months at Company's discretion.
Autonomix Medical raises $2.5M via warrant exercise inducement, issues new Series B warrants
Existing warrant exercise price reduced to $1.723/share; holders exercise/prepay for 1,477,596 shares.
Autonomix PoC1 trial meets objectives; initiates PoC2 expansion study for visceral cancer pain
All 20 patients enrolled; 19 treated via transvascular RF ablation; 84% femoral-access responders achieved 53.3% mean VAS pain reduction at 7 days.
Autonomix Medical enters $2.1M ATM equity facility; reverse split share dispute
Entered ATM sales agreement with Ladenburg Thalmann for up to $2.1M of common stock; 3.0% agent commission.
Net loss of $2.7M for Q3 ended Dec 31, 2024 vs $3.1M a year ago; nine-month net loss $8.2M vs $10.0M.
Autonomix Medical raises $10.0M in underwritten public offering of common and pre-funded units
Gross proceeds of ~$10.0M from 615,500 common units (incl. 156,809 over-allotment) and 917,596 pre-funded units.
Net loss of $2.8M for three months ended Sept 30, 2024 vs $6.0M loss same quarter last year; cash $5.2M.
Autonomix Medical disputes DTCC demand for 271,846 shares after reverse split
Completed 1-for-20 reverse stock split on Oct 24, 2024; no fractional shares, rounding to full share.
Autonomix Medical to effect 1-for-20 reverse stock split effective Oct 24, 2024
Stockholders approved reverse split ratio range 1:2 to 1:50; board selected 1:20.
Autonomix Medical receives Nasdaq bid price deficiency notice; 180 days to regain $1.00 minimum
Received Nasdaq deficiency letter on Sept. 16, 2024, for bid price below $1.00 for 30 consecutive business days.
Net loss $2.7M vs $0.9M YoY; cash $6.8M as of June 30, 2024.
Autonomix licenses FDA-cleared ablation technology; issues 250,000 shares to RF Innovations
Licensed intellectual property for Apex 6 Radiofrequency Generator, an FDA-cleared ablation device for peripheral nerve pain.
60% of lead-in patients responded with mean 6.33 VAS pain reduction (8.0 to 1.67) at 7 days post-procedure.
Autonomix names Brad Hauser CEO; grants 900k-share inducement option; Bisson becomes Vice Chair
Brad Hauser appointed CEO and President; base salary $450,000, target bonus 60%.
Net loss $15.4M vs $2.0M prior year, including $8.0M non-cash warrant loss; G&A $5.2M, R&D $2.2M.
Autonomix Medical closes $11.2M IPO, regains cardiology rights via $8M warrant deal
IPO closed Jan 26: 2,234,222 shares at $5.00, gross proceeds $11,171,110 before expenses.
entered into an employment agreement with Brad Hauser pursuant to which Mr. Hauser agreed to serve as the Company’s chief executive officer and president
Max materiality 0.85 · Median 0.65 · Most common event other_material